The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status

Ricky M. Trigg(GlaxoSmithKline (United Kingdom)), Suzanne D. Turner(Unknown)

Nature Communications

November 28, 2019

10.1038/s41467-019-13315-x

Cited by 42

Related Papers

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond

|Cancers|2018|86

Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma

|American Journal Of Pathology|2019|54

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

|Nature Communications|2024|14

Aberrant Anaplastic Lymphoma Kinase Activity Induces a p53 and Rb-Dependent Senescence-Like Arrest in the Absence of Detectable p53 Stabilization

|PLoS ONE|2011|4